Living Cell Technologies Limited (LCT)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Living Cell Technologies Limited
Stock Code: LCT
GICS Sub-Industry: Biotechnology
Market Cap ($M): 24
Equiv. Shares (M): 357

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.067 $ 0.064 $ 0.067 $ 0.064 $ 0.064 60,000 $ 0.003  4.688 %

Company Overview

Business Description:
Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL¬ģ for the treatment of type 1 diabetes and NTCELL¬ģ, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson‚Äôs disease.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -6.8 -1.9 -- 0.0 0.0 0.0 --
2013  A -3.0 -0.8 -147.1 0.0 0.0 0.0 --
2012  A 5.7 1.7 -- 3.7 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Bionomics (BNO) $240 M -- 6.3247 0.3032 74.6753 10.1950 7.8231 0.00 0.00 0.00
CSL (CSL) $34,458 M 0.0899 0.1803 0.1256 25.4139 21.5315 19.1284 1.65 1.96 2.16
Living Cell (LCT) $23 M -- -- -- -- -- -- 0.00 -- --
Mesoblast (MSB) $1,582 M -- -- -- -- -- -- 0.00 0.00 0.00
Sirtex Medical (SRX) $1,237 M 0.2906 0.5104 0.3721 53.0266 35.1074 25.5871 0.00 0.83 1.37

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
LCT -- -- 2.84 -- 3.24
Market 1.13 14.0 0.99 1.03 3.64
Sector 0.69 22.2 3.19 1.36 8.75

Name Position Start Date
Professor Robert Bartlett Elliott Medical Director 15 January 2004
Mr Robert Moyse Willcocks Non-Executive Director 29 March 2011
Mr Laurrie Hunter Non-Executive Director 25 August 2006
Dr Bernard Tuch Non-Executive Director 19 July 2011
Mr Roy James Austin Non-Executive Director,Non-Executive Chairman 25 February 2011

Name Position
Kenneth (Ken) P Taylor Chief Executive Officer
Nicholas (Nick) John Victor Geddes Company Secretary
John Cowan Head of Finance & Administration

Substantial Shareholders
Holding Name
25,000,000 (7.00%) Otsuka Pharmaceutical Factory, Inc
24,150,408 (6.76%) Palmert Members Limited
24,150,408 (6.76%) Coalco International Limited
25,610,891 (7.17%) Persistency Private Equity Limited (formerly Prospector Limited)
12,329,061 (3.45%) K One W One Limited

Calendar of Events
Date Event
14 August 2015 Report (Prelim)
24 February 2015 Report (Interim)
14 October 2014 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Estate Planning

Everyone wants their financial affairs to be in the best possible state when they die so that their loved ones can enjoy the benefits of their legacy without dispute or conflict.

More details...


Billionaires bankroll Ten's new direction Media Network sees digital future

The Age 19/12/2013 | Ten Network's programming ambitions will be funded by a $200 million loan guaranteed by three of its billionaire owners, as the free-to-air broadcaster declared digital was the future and pointed to early signs that its switch to an older market demographic was working.

Elders alleges $24m fraud in live cattle division

The Age 19/12/2013 | Troubled rural services group Elders is threatening to call in the police over an alleged $24 million fraud by a "handful of individuals" in its live cattle exports division.

Bega Cheese holds back in three-way bidding war for WCB

The Age 19/12/2013 | Bega Cheese began the battle for Warrnambool Cheese & Butter but three months on it appears to be the first casualty of the bidding war.

Aussie hampers transition

The Age 19/12/2013 | A persistently high Australian dollar is thwarting the Reserve Bank's efforts to ease the transition of the economy away from mining.

RBA keeps its focus on lower dollar

The Age 19/12/2013 | The Reserve Bank is keeping the door open to further interest rate cuts, but believes the "significant amount" of monetary policy easing over the past two years is already stimulating growth.

Pact's struggles weigh down Orora

The Age 19/12/2013 | The underwhelming sharemarket debut of packaging company Pact Group Holdings has weighed on the demerger of Amcor and its $2 billion Australasian packaging and distribution business Orora.


Sponsored Links